Founded in 2010, 바카라 사이트 is a biotechnology company focused on developing RNA interference (RNAi)-based therapeutics. The company leverages three proprietary platforms—asiRNA, cp-asiRNA, and GalNAc-asiRNA—to expand its pipeline across a range of diseases.
바카라 사이트’s lead program, OLX702A, is a GalNAc-asiRNA therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The drug inhibits the MARC1 gene, a target identified through genome-wide association studies (GWAS), and is designed for targeted delivery to hepatocytes via a GalNAc ligand. In preclinical models, OLX702A improved liver fibrosis and reduced body weight. The candidate is currently in Phase 1 trials in Australia, and in February 2025, it was licensed to Eli Lilly in a deal valued at approximately 0 million.
Another advanced candidate, OLX101A, targets connective tissue growth factor (CTGF) for the treatment of hypertrophic scars. Administered intradermally, it completed Phase 2 trials in the U.S., showing significant clinical efficacy by reducing POSAS scores in patients with post-cesarean and post-surgical scars.
OLX104C is being developed for male pattern baldness, targeting androgen receptors (AR) involved in hair loss. Delivered intradermally to minimize systemic side effects, the therapy showed a strong safety profile and durable effects in Phase 1a trials in Australia.
The company is also advancing OLX301A, an ophthalmic RNAi candidate for age-related macular degeneration (AMD). It operates through a first-in-class MyD88 inhibition mechanism, aimed at both dry and wet AMD. OLX301A is currently in Phase 1 trials in the U.S.
Beyond its clinical-stage programs, 바카라 사이트 is actively developing preclinical assets including: OLX304C for retinitis pigmentosa, OLX40X for neurodegenerative diseases and neuropathic pain, and a cp-asiRNA program targeting adipocytes for obesity management.
